To develop novel drug candidates against multiple targets across different therapeutic areas
NovAliX, a provider of chemistry and biophysical technologies to the pharmaceutical industry, has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma of Tokyo, Japan.
Under the alliance both companies will develop novel drug candidates against multiple targets across different therapeutic areas.
NovAliX, based in Illkirch, France, will initially use its protein biochemistry expertise in combination with its biophysical technology platform, applying its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterisation of selected small molecule hit structures.
NovAliX will receive technology access fees as well as research funding payments.
The financial terms of the deal have not revealed.
Stephan Jenn, president of NovAliX, said: ‘This integrated collaboration represents a significant milestone as Teijin is the second Japanese pharmaceutical company to partner with us this year. This alliance underlines again the competitive edge of our scientific expertise and biophysical technologies as well as our commitment to serve the Japanese pharmaceutical research market that is strongly driven by science and innovation.’